In this episode, Pr. Daniela Cesselli (University of Udine) discusses the strategic needs that drove the adoption of a CGP panel and the reasons behind choosing the 𝗢𝗻𝗰𝗼𝗗𝗘𝗘𝗣® 𝗞𝗶𝘁 solution. Was it to ensure timely results while covering HRD, TM, and MSI testing? To leverage an optimized workflow that enables labs to sequence more samples within the same timeframe? Or perhaps for its responsive support, which operates like a true “guardian angel”?
Poster
Clinical validation on the PAOLA-1/ENGOT-ov25 cohort of HRD calculation performed with the OncoDEEP® Kit comprehensive genomic panel.
The PAOLA-1/ENGOT-ov25 cohort is a pivotal clinical trial investigating maintenance therapy with olaparib and bevacizumab in patients with advanced ovarian cancer. A key outcome of the study is the significantly improved progression-free survival observed in...
